However, one study into the use of one of these medications, Mounjaro, found that approximately 500,000 people in the UK have used the drug privately for weight loss since 2023
Notably: BPC-157, KPV, MOTs-C, Emideltide (DSIP), Epitalon, Semax (heptapeptide) and TB-500 are among those expected to be reviewed in July 2026 Other substances, including Cathelicidin LL-37, Dihexa Acetate, PEG-MGF, GHK-Cu and Melanotan II, are under consideration for review by early 2027 Non-injectable GHK-Cu is following a slightly different path, with separate evaluation anticipated before February 2027
This means you feel satisfied longer after eating and are less likely to overeat
It reflects a direct-to-consumer supplement sales funnel with several details buyers should verify before purchasing - who you're actually contracting with, which purchase option you've selected, which return policy actually applies, and what price you're really being offered today versus what a countdown clock implies